Clinical trials: Immunologic Disease
Seasonal Allergic Rhinitis
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
The purpose of this study is to determine if the combination of two allergy medications (formulated azelastine/fluticasone product)is more effective than placebo or either component medication alone (azelastine or fluticasone).
- Trial name
- NCT00883168
- Testing
- azelastineHcl, fluticasone propionate, azelastine Hcl/fluticasone propionate
- Where
- 45 sites in United States
- Volunteers
- 1,791 people
- Sponsor
- Meda Pharmaceuticals
Myasthenia Gravis
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of IM-101 in adult participants with AChR antibody-positive gMG.
- Trial name
- Synergy-MG (NCT07250750)
- Testing
- IM-101 Part A, IM-101 Part B
- Where
- 25 sites in United States, Bulgaria and 4 more
- Volunteers
- 96 people
- Sponsor
- ImmunAbs Inc.
Thyroid Eye Disease, TED
Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in…
- Trial name
- SatraGO-1 (NCT05987423)
- Testing
- Satralizumab
- Where
- 46 sites in United States, Argentina and 8 more
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha
During the Core Phase of the study, participants received STI571 at a dose of 400 milligrams (mg) daily for up to 12 months. Participants completing 12 months of therapy were eligible to continue treatment in the Extension Phase…
- Trial name
- NCT00171223
- Testing
- STI571
- Where
- 28 sites in United States, France and 4 more
- Volunteers
- 532 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Dose Finding Trial to Assess the Efficacy and Safety of SOTB07 in Persistent Asthma
This study is a dose finding trial to assess the efficacy and safety of SOTB07 in persistent asthma.
- Trial name
- NCT00936624
- Testing
- SOTB07, montelukast
- Where
- South Korea
- Volunteers
- 245 people
- Sponsor
- SK Chemicals Co., Ltd.
Insulin-dependent Diabetes Mellitus, Diabetes Mellitus, Type 1
DreaMed Advisor Pro System in Subjects With Type 1 Diabetes Treated With MDI Therapy
A multi center, open label, prospective study that will include up to 100 subjects with Type 1 Diabetes treated with Multiple Daily Injections (MDI) of insulin according to a predefined sliding scale plan or carbohydrate ratio…
- Trial name
- NCT04043260
- Testing
- Advisor Pro
- Where
- Israel
- Volunteers
- 35 people
- Sponsor
- DreaMed Diabetes
Allergy
Efficacy and Tolerability of Two Different Administration Routes With SLITonePLUS Birch
Multicentre Phase II trial, comparing two different administration routes of SLITonePLUS Birch in regard to pharmacodynamic efficacy and tolerability.
- Trial name
- NCT01191359
- Testing
- oral immunotherapy
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- ALK-Abelló A/S
Asthma
First Step With Singulair® Therapy (0476-323)
In adult patients with mild persistent asthma, singulair® 10 mg will be at least as effective as low dose Inhaled Corticosteroids (ICS) in improving asthma symptom control or satisfaction over a 6 week comparison period.
- Trial name
- FIRST (NCT00545324)
- Testing
- MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks, Comparator: Fluticasone / Duration of Treatment: 6 Weeks
- Volunteers
- 399 people
- Sponsor
- Organon and Co
Asthma
Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.
This study will evaluate the safety and efficacy of omalizumab up to 48 weeks in adult patients with moderate to severe bronchial asthma. THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES
- Trial name
- NCT00219323
- Testing
- Omalizumab
- Where
- Japan
- Volunteers
- 133 people
- Sponsor
- Novartis
Autoimmune Diseases, Multiple Sclerosis
First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641
A Phase I First-in-Human, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate Safety, Tolerability, and Pharmacokinetics after Single and Multiple Oral Dose of LPX-TI641.
- Trial name
- NCT05853835
- Testing
- LPX-TI641
- Where
- 2 sites in United States, Jordan
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- LAPIX Therapeutics Inc.
Rheumatoid Arthritis
A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor
The current study is designed to evaluate the safety and efficacy, including MRI imaging, across a range of VX-509 doses in subjects with active rheumatoid arthritis (RA) who have had an inadequate response to disease-modifying…
- Trial name
- NCT01754935
- Testing
- VX-509
- Where
- 30 sites in United States, Denmark and 4 more
- Volunteers
- 43 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Chronic, Non Malignant Pain
Open Label, Safety Study of EN3270 in Patients With Moderate to Severe Non-malignant, Chronic Pain
Two stage study looking at different titration schedules in patients with moderate to severe non-malignant chronic pain. Up to 80 patients at approximately 15 centers in the US to be enrolled.
- Trial name
- NCT00485225
- Testing
- EN3270
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Durect
Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.
This study aimed to assess the optimal duration of nilotinib 300 mg twice daily (BID) consolidation treatment in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML), in order that patients remained…
- Trial name
- ENESTPath (NCT01743989)
- Testing
- Nilotinib
- Where
- 208 sites in Austria, Belgium and 19 more
- Volunteers
- 620 people
- Sponsor
- Novartis Pharmaceuticals
Mild and Moderate Alzheimer's Disease, Cognitively Healthy People
An Exploratory Study to Compare the Differences in Nutritional Status Between Patients With Mild and Moderate Alzheimer's Disease (AD) and Cognitively Intact Healthy People in an Asian Population
Difference in nutritional status between patients with mild and moderate Alzheimer's Disease (AD) and cognitively intact healthy people in an Asian population
- Trial name
- NCT02249468
- Where
- Singapore
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- Danone Nutricia Research
Lupus Erythematosus, Systemic
A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus
The purpose of this study is to evaluate the amount of tabalumab in the blood after it is given by two different injection methods - A traditional syringe or a spring loaded syringe for 12 weeks.
- Trial name
- NCT02041091
- Testing
- Tabalumab Auto-Injector, Tabalumab Prefilled Syringe
- Where
- 44 sites in United States, Puerto Rico and 1 more
- Volunteers
- 226 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Diabetes Technology Study of Real-Time Glucose Alerts in the Team Management of Diabetes
Many people with diabetes have a desire to share blood glucose data with other members of their team. Using a unique wireless glucose meter device, real-time wireless alerts may be automatically sent to a specific team of…
- Trial name
- NCT00322478
- Testing
- Automated informatics driven education and social networking, Blood Glucose Notifications to Remote Caregivers, Frequency of Pattern Management
- Where
- United States
- Volunteers
- 432 people
- Sponsor
- Diabetech
Atopic Dermatitis
Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis
This is an open-label, safety study designed to assess the multiple-dose pharmacokinetics and potential for adrenal suppression following topical treatment with halobetasol propionate 0.05% spray applied twice-daily in adult…
- Trial name
- NCT03245385
- Testing
- Treatment with Halobetasol propionate 0.05% topical spray
- Where
- 13 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Sjogren's Syndrome
Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome
This study will evaluate the safety and tolerability of iscalimab at two dose levels in patients with Sjögren's Syndrome, who participated in the TWINSS core study, CCFZ533B2201 (NCT03905525).
- Trial name
- TWINSS Extn (NCT04541589)
- Testing
- Iscalimab
- Where
- 62 sites in United States, Argentina and 21 more
- Volunteers
- 206 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, Healthy
A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354
To compare bioavailability and pharmacokinetics of CAT-354 following subcutaneous administration compared with intravenous administration.
- Trial name
- NCT00638989
- Testing
- CAT-354 150 mg (intravenous), CAT-354 150 mg (subcutaneous), CAT-354 300 mg (subcutaneous)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Asthma
A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults
The medications being used in this study are individually approved by the Food and Drug Administration (FDA). The medication under investigation is a combination of two medications in one inhaler.
- Trial name
- NCT00649025
- Testing
- FlutiForm 250/10, SKP-Fluticasone, Flovent Fluticasone HFA
- Where
- 103 sites in United States, Argentina and 8 more
- Volunteers
- 438 people
- Sponsor
- SkyePharma AG